Bioengineered blood vessel for Coronary Bypass Sustains 18-Month Patency — With a Full Year without Blood Thinners

Nature Communications study reports an off-the-shelf bioengineered coronary conduit that remained patent for 18 months after anticoagulation was withdrawn, advancing a ready-to-use alternative for the hundreds of thousands of patients who undergo coronary bypass each year ST. PAUL, Minn., Aug. 21, 2026 (GLOBE NEWSWIRE) — Vascudyne, Inc. today announced the publication in Nature Communications of…